Clonal Hematopoiesis and Leukemia Research

We are part of the Biological Sciences Division and the Section of Hematology/Oncology within the Department of Medicine at the University of Chicago. Our goal is to eradicate leukemia by finding curative therapies and developing preventative strategies.

Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the presence of gene mutations in blood cells of an individual in the absence of a blood cancer. Individuals who receive chemotherapy or radiation therapy for a solid tumor or autoimmune disease are at high risk for CHIP. Our lab has shown that CHIP is a precursor lesion for acute leukemias of both myeloid (AML) and lymphoid (ALL) origin. Individuals with CHIP are at significantly higher risk of developing blood cancers and inflammation-related diseases (such as heart attack, stroke, autoimmune disease) compared to individuals without CHIP. Our research aims to identify mechanisms by which CHIP progresses to full-blown acute leukemia. We also try to understand how CHIP drives inflammation in human body so that we can develop new strategies to mitigate its adverse multisystem effects.

Using patient samples and laboratory models of leukemia, we discover critical pathways that drive the initiation and progression of leukemia. We use and generate new cutting edge technology to gain important biologic insights and develop new drugs. Therefore, our multidisciplinary team of scientists and clinicians work towards the goal of a leukemia-free world.